Nectar Lifesciences: Revised target of Rs48

Net sales for the quarter increased to Rs2416.7 mn compared to Rs1722.9 mn in Q4FY09; an increase of 40.3% primarily led by the growth in the API segment in both domestic and international markets. Fairwealth re-rates the stock with a revised target price of Rs 48

http://migre.me/L59q